Current Rheumatology Reports
Latest Publications


TOTAL DOCUMENTS

1830
(FIVE YEARS 248)

H-INDEX

65
(FIVE YEARS 9)

Published By Springer-Verlag

1534-6307, 1523-3774

2021 ◽  
Vol 23 (12) ◽  
Author(s):  
Jesse Y. Dabit ◽  
Maria O. Valenzuela-Almada ◽  
Sebastian Vallejo-Ramos ◽  
Alí Duarte-García

2021 ◽  
Vol 23 (12) ◽  
Author(s):  
Augustin Latourte ◽  
Julien Dumurgier ◽  
Claire Paquet ◽  
Pascal Richette
Keyword(s):  

2021 ◽  
Vol 23 (12) ◽  
Author(s):  
Eleni Xourgia ◽  
Maria G. Tektonidou

2021 ◽  
Vol 23 (11) ◽  
Author(s):  
Wei Tang ◽  
Yevgeniya Gartshteyn ◽  
Edd Ricker ◽  
Sean Inzerillo ◽  
Shane Murray ◽  
...  

2021 ◽  
Vol 23 (11) ◽  
Author(s):  
Lily Pollock ◽  
Ashley Ridout ◽  
James Teh ◽  
Colin Nnadi ◽  
Dionisios Stavroulias ◽  
...  

Abstract Purpose of Review Marfan syndrome (MFS) is an autosomal dominant heritable disorder of fibrillin-1 (FBN1) with predominantly ocular, cardiovascular, and musculoskeletal manifestations that has a population prevalence of approximately 1 in 5–10,000 (Chiu et al. Mayo Clin Proc. 89(1):34–42, 146, Dietz 3, Loeys et al. J Med Genet. 47(7):476–85, 4). Recent Findings The vascular complications of MFS still pose the greatest threat, but effective management options, such as regular cardiac monitoring and elective surgical intervention, have reduced the risk of life-threatening cardiovascular events, such as aortic dissection. Although cardiovascular morbidity and mortality remains high, these improvements in cardiovascular management have extended the life expectancy of those with MFS by perhaps 30–50 years from an estimated mean of 32 years in 1972 (Dietz 3, Gott et al. Eur J Cardio-thoracic Surg. 10(3):149–58, 147, Murdoch et al. N Engl J Med. 286(15):804–8, 148). The musculoskeletal manifestations of MFS, which to date have received less attention, can also have a significant impact on the quality of life and are likely to become more important as the age of the Marfan syndrome population increases (Hasan et al. Int J Clin Pract. 61(8):1308–1320, 127). In addition, musculoskeletal manifestations are often critically important in the diagnosis of MFS. Summary Here, we review the main clinically relevant and diagnostically useful musculoskeletal features of MFS, which together contribute to the “systemic features score” (referred to hereafter as systemic score), part of the revised Ghent nosology for MFS. We discuss current treatment strategies and highlight the need for a multidisciplinary approach to diagnosis and management. Finally, we review new pharmacological approaches that may be disease modifying and could help to improve the outcome for individuals with this syndrome.


2021 ◽  
Vol 23 (11) ◽  
Author(s):  
Ali Mobasheri ◽  
Armaghan Mahmoudian ◽  
Ursule Kalvaityte ◽  
Ilona Uzieliene ◽  
Christina E. Larder ◽  
...  

Abstract Purpose of Review Osteoarthritis (OA) is the most common forms of arthritis in the general population, accounting for more pain and functional disability than any other musculoskeletal disease. There are currently no approved disease modifying drugs for OA. In the absence of effective pharmacotherapy, many patients with OA turn to nutritional supplements and nutraceuticals, including collagen derivatives. Collagen hydrolyzates and ultrahydrolyzates are terms used to describe collagens that have been broken down into small peptides and amino acids in the presence of collagenases and high pressure. Recent Findings This article reviews the relevant literature and serves as a White Paper on collagen hydrolyzates and ultrahydrolyzates as emerging supplements often advertised to support joint health in OA. Collagen hydrolyzates have demonstrated some evidence of efficacy in a handful of small scale clinical trials, but their ability to treat and reverse advanced joint disease remains highly speculative, as is the case for other nutritional supplements. Summary The aim of this White Paper is to stimulate research and development of collagen-based supplements for patients with OA and other musculoskeletal diseases at academic and industrial levels. This White Paper does not make any treatment recommendations for OA patients in the clinical context, but simply aims to highlight opportunities for scientific innovation and interdisciplinary collaboration, which are crucial for the development of novel products and nutritional interventions based on the best available and published evidence.


2021 ◽  
Vol 23 (10) ◽  
Author(s):  
Jeremy Sullivan ◽  
Michael H. Pillinger ◽  
Michael Toprover
Keyword(s):  

2021 ◽  
Vol 23 (10) ◽  
Author(s):  
Mohamad Bittar ◽  
Wai Chung Yong ◽  
Marina Magrey ◽  
Muhammad Asim Khan

Sign in / Sign up

Export Citation Format

Share Document